KLRS
Kalaris Therapeutics IncNASDAQHealthcare$5.79-2.44%ClosedMarket Cap: $108.3M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.68
P/S
0.00
EV/EBITDA
-0.27
DCF Value
$6.25
FCF Yield
-39.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-73.1%
ROA
-35.7%
ROIC
-41.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-10.0M | $-0.44 |
| FY 2025 | $0.00 | $-43.4M | $-2.85 |
| Q3 2025 | $0.00 | $-11.9M | $-0.64 |
| Q2 2025 | $0.00 | $-11.3M | $-0.61 |
Trading Activity
Insider Trades
View AllHagen Brett Rofficer: Chief Accounting Officer
SellMon Mar 23
Hagen Brett Rofficer: Chief Accounting Officer
SellMon Mar 23
Oxtoby Andrewdirector, officer: See Remarks
SellFri Mar 20
Gall Matthewofficer: Chief Financial Officer
SellFri Mar 20
Feinsod Matthewofficer: Chief Medical Officer
SellFri Mar 20
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.14
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.